Trial Profile
A Phase I Study to Assess the Safety and Immunogenicity of Prime-boost Immunisations With Vaccine Candidates AdCh3NSmut1 and MVA-NSmut in HIV-1 Seropositive HCV-uninfected Adults on Antiretroviral Therapy (ART)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2023
Price :
$35
*
At a glance
- Drugs Hepatitis C vaccine (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 10 Oct 2018 Status changed from active, no longer recruiting to completed.
- 02 May 2017 Planned End Date changed from 1 Feb 2017 to 1 Oct 2017.
- 02 May 2017 Status changed from recruiting to active, no longer recruiting.